Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...

This was the stock's third consecutive day of losses.

Bristol Neuroscience will be hosting a number of high-profile speakers for the 2024-25 academic year.